Elsevier

The Lancet

Volume 342, Issue 8871, 4 September 1993, Pages 618-619
The Lancet

Letters to the Editor
Negligible excretion of 5-aminosalicylic acid in breast milk

https://doi.org/10.1016/0140-6736(93)91443-PGet rights and content

References (3)

There are more references available in the full text version of this article.

Cited by (40)

  • The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy

    2016, Gastroenterology
    Citation Excerpt :

    In addition, a meta-analysis201 and more recent case-control studies202,203 have suggested that breast-feeding may have a protective effect against the development of early-onset IBD in the offspring. Data suggest that the amount of 5-ASA preparations and sulfasalazine metabolites excreted in breast milk is low, and they are considered safe to use while breast-feeding.15,204–207 Corticosteroids are found in low concentrations in breast milk,208,209 and although several guidelines suggest that women be advised to avoid breast-feeding within 4 hours of drug administration,15,116 this consensus group did not.

  • Gastrointestinal drugs

    2015, Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment: Third Edition
  • Update on pregnancy and breastfeeding in the era of biologics

    2013, Digestive and Liver Disease
    Citation Excerpt :

    Folic acid supplementation has been shown to reduce the risk of cleft palate and cardiovascular teratogenicity [42]. The amount of aminosalicylate metabolites excreted in breast milk is negligible, and is considered low risk for nursing [43]. In men, sulfasalazine induces oligospermia and abnormal sperm morphology and function, which can lead to impaired fertility.

  • Gastrointestinal Drugs

    2007, Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment: Second Edition
  • Gastrointestinal drugs

    2007, Drugs During Pregnancy and Lactation
View all citing articles on Scopus
View full text